SLN and NLC for topical, dermal, and transdermal drug delivery

dc.commentsCEB53514por
dc.contributor.authorSouto, Eliana B.por
dc.contributor.authorBaldim, Iarapor
dc.contributor.authorOliveira, Wanderley P.por
dc.contributor.authorRao, Rekhapor
dc.contributor.authorYadav, Niteshpor
dc.contributor.authorGama, F. M.por
dc.contributor.authorMahant, Sheefalipor
dc.date.accessioned2020-03-02T15:54:09Z
dc.date.embargo10000-01-01
dc.date.issued2020-02-17
dc.date.updated2020-02-22T20:43:16Z
dc.description.abstractIntroduction: From a biopharmaceutical standpoint, the skin is recognized as an interesting route for drug delivery. In general, small molecules are able to penetrate the stratum corneum, the outermost layer of the skin. In contrast, the delivery of larger molecules, such as peptides and proteins, remains a challenge. Nanoparticles have been exploited not only to enhance skin penetration of drugs but also to expand the range of molecules to be clinically used.Areas covered: This review focus on Solid lipid nanoparticles (SLN) and Nanostructured lipid carriers (NLC) for skin administration. We discuss the selection criteria for lipids, surfactants, and surface modifiers commonly in use in SLN/NLC, their production techniques, and the range of drugs loaded in these lipid nanoparticles for the treatment of skin disorders.Expert opinion: Depending on the lipid and surfactant composition, different nanoparticle morphologies can be generated. Both SLN and NLC are composed of lipids that resemble those of the skin and sebum, which contribute to their enhanced biocompatibility, with limited toxicological risk. SLN and NLC can be loaded with very chemically different drugs, may provide a tunable release profile, can be produced in a sterilized environment, and be scaled-up without the need for organic solvents.por
dc.description.publicationversioninfo:eu-repo/semantics/publishedVersion
dc.description.sponsorshipThe authors acknowledge CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) for the financial support and for the fellowship of the second author (88887.368385/2019-00). Authors also acknowledge the support received from the Portuguese Science and Technology Foundation, Ministry of Science and Education (FCT/MEC) through national funds, and co-financed by FEDER, under the Partnership Agreement PT2020, for the projects M-ERA-NET-0004/2015-PAIRED and UIDB/04469/2020 (strategic fund).por
dc.distributioninternationalpor
dc.identifier.citationSouto, Eliana; Baldim, Iara; Oliveira, Wanderley P.; Rao, Rekha; Yadav, Nitesh; Gama, F. M.; Mahant, Sheefali, SLN and NLC for topical, dermal, and transdermal drug delivery. Expert Opinion on Drug Delivery, 17(3), 357-377, 2020por
dc.identifier.doi10.1080/17425247.2020.1727883por
dc.identifier.issn1742-5247por
dc.identifier.pmid32064958por
dc.identifier.urihttps://hdl.handle.net/1822/64156
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherTaylor and Francispor
dc.relationUIDB/04469/2020por
dc.relation.publisherversionhttps://www.tandfonline.com/toc/iedd20/currentpor
dc.rightsrestrictedAccesspor
dc.subjectSolid lipid nanoparticlespor
dc.subjectnanostructured lipid carrierspor
dc.subjectskin administrationpor
dc.subjectlipidspor
dc.subjectsurfactantspor
dc.subject.wosScience & Technologypor
dc.titleSLN and NLC for topical, dermal, and transdermal drug deliverypor
dc.typearticle
dspace.entity.typePublicationen
oaire.citationEndPage377por
oaire.citationIssue3por
oaire.citationStartPage357por
oaire.citationVolume17por
sdum.journalExpert Opinion on Drug Deliverypor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
document_53514_1.pdf
Tamanho:
1.85 MB
Formato:
Adobe Portable Document Format